↓ Skip to main content

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1776-x
Pubmed ID
Authors

Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, Richard Greil, Alexander Egle

Abstract

Induction chemotherapy incorporating docetaxel, cisplatin and 5- fluorouracil before radiotherapy may improve the outcome of patients with advanced head and neck cancer. Nevertheless, the addition of docetaxel increases hematological toxicity and infectious complications. Therefore, genetic markers predicting toxicity and efficacy of this treatment regimen may help to identify patients, who would have the most benefit from this intensive treatment. A cohort of 78 patients with advanced head and neck cancer treated with induction chemotherapy was assessed for clinical outcome and toxicity during treatment with curative intention. Genetic polymorphisms primary associated with treatment efficacy (ERCC2-rs13181, rs1799793, ERCC1-rs3212986, rs11615, XRCC1-rs25487) or with docetaxel caused toxicity (CYP39A1-rs7761731, SLCO1B3-rs11045585) were evaluated in all patients. The results of these analyses were correlated with the clinical outcome of the patients (loco regional control, progression free survival, overall survival) and treatment related toxicity during induction chemotherapy. Median progression free survival and overall survival was 20 and 31 months in an intention to treat analysis, respectively. Overall response rate to induction chemotherapy was high with 78.1 % of all patients. None of the polymorphisms tested was associated with the clinical outcome of the patients. Genotype A of the CYP39A1 rs7761731 polymorphism was associated with a higher incidence of leucopenia and infections or death during induction chemotherapy. Intensive induction chemotherapy results in a high response rate in the majority of patients. None of the polymorphisms tested was associated with the clinical outcome of the patients. The CYP39A1 polymorphism rs7761731 may help to identify patients at high risk for treatment related toxicity.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 4%
Unknown 27 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 18%
Student > Master 4 14%
Student > Doctoral Student 3 11%
Other 3 11%
Student > Bachelor 2 7%
Other 8 29%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 13 46%
Biochemistry, Genetics and Molecular Biology 5 18%
Pharmacology, Toxicology and Pharmaceutical Science 4 14%
Chemistry 1 4%
Materials Science 1 4%
Other 0 0%
Unknown 4 14%